EP0293936B1 - Tissue plasminogen activator analogs having modified growth factor domains - Google Patents

Tissue plasminogen activator analogs having modified growth factor domains Download PDF

Info

Publication number
EP0293936B1
EP0293936B1 EP88108951A EP88108951A EP0293936B1 EP 0293936 B1 EP0293936 B1 EP 0293936B1 EP 88108951 A EP88108951 A EP 88108951A EP 88108951 A EP88108951 A EP 88108951A EP 0293936 B1 EP0293936 B1 EP 0293936B1
Authority
EP
European Patent Office
Prior art keywords
analog
domain
native
dna
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP88108951A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0293936A3 (en
EP0293936A2 (en
Inventor
Eileen R. Mulvihill
Patrick J. O'hara
Bjorn A. Nexo
Shinji Yoshitake
Yasunori Ikeda
Suguru Suzuki
Akira Hashimoto
Teruaki Yuzuriha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Eisai Co Ltd
Zymogenetics Inc
Original Assignee
Novo Nordisk AS
Eisai Co Ltd
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Eisai Co Ltd, Zymogenetics Inc filed Critical Novo Nordisk AS
Publication of EP0293936A2 publication Critical patent/EP0293936A2/en
Publication of EP0293936A3 publication Critical patent/EP0293936A3/en
Application granted granted Critical
Publication of EP0293936B1 publication Critical patent/EP0293936B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Integrated Circuits (AREA)
EP88108951A 1987-06-04 1988-06-03 Tissue plasminogen activator analogs having modified growth factor domains Expired - Lifetime EP0293936B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5806187A 1987-06-04 1987-06-04
US58061 1987-06-04
US16284788A 1988-03-02 1988-03-02
US162847 1988-03-02

Publications (3)

Publication Number Publication Date
EP0293936A2 EP0293936A2 (en) 1988-12-07
EP0293936A3 EP0293936A3 (en) 1989-09-20
EP0293936B1 true EP0293936B1 (en) 1995-02-22

Family

ID=26737188

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88108951A Expired - Lifetime EP0293936B1 (en) 1987-06-04 1988-06-03 Tissue plasminogen activator analogs having modified growth factor domains

Country Status (14)

Country Link
US (1) US5403734A (no)
EP (1) EP0293936B1 (no)
JP (1) JPS6485079A (no)
KR (1) KR0135427B1 (no)
AT (1) ATE118815T1 (no)
AU (1) AU625752B2 (no)
CA (1) CA1341446C (no)
DE (1) DE3853100T2 (no)
DK (1) DK302388A (no)
ES (1) ES2069536T3 (no)
FI (1) FI101306B (no)
IE (1) IE67036B1 (no)
NO (1) NO179874C (no)
NZ (1) NZ224914A (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756093A (en) * 1985-04-22 1998-05-26 Genentech, Inc. Tissue plasminogen activator variants
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
US5736134A (en) * 1985-04-22 1998-04-07 Genentech, In.C Tissue plasminogen activator variants
DE3851259T2 (de) * 1987-06-04 1994-12-15 Zymogenetics Inc Mutierter t-PA mit Kringle-Ersatz.
GB8815135D0 (en) * 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
JPH0595786A (ja) * 1991-10-07 1993-04-20 Green Cross Corp:The 変異ヒトプロウロキナーゼ
DE10199044I2 (de) * 1992-06-03 2006-02-09 Genentech Inc Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
CA2807749C (en) * 2010-08-05 2023-02-28 Council Of Scientific & Industrial Research Protein fusion constructs possessing thrombolytic and anticoagulant properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
DK149786A (da) * 1985-04-04 1986-10-04 Beecham Group Plc Proteolytisk enzym
FR2581652B1 (fr) * 1985-04-22 1989-12-22 Genentech Inc Nouveaux mutants de l'activateur tissulaire du plasminogene humain
US4916071A (en) * 1985-08-14 1990-04-10 American Home Products Corporation Poly-kringle plasminogen activator
JP2527454B2 (ja) * 1986-01-31 1996-08-21 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新しい血栓溶解タンパク質
US5376547A (en) * 1987-01-30 1994-12-27 American Home Products Corporation Des-epidermal growth factor plasminogen activators

Also Published As

Publication number Publication date
KR0135427B1 (ko) 1998-04-23
AU1743088A (en) 1988-12-08
EP0293936A3 (en) 1989-09-20
JPH0448434B2 (no) 1992-08-06
EP0293936A2 (en) 1988-12-07
JPS6485079A (en) 1989-03-30
ES2069536T3 (es) 1995-05-16
FI882627A0 (fi) 1988-06-03
NO882454L (no) 1988-12-05
NO179874C (no) 1997-01-02
CA1341446C (en) 2003-11-18
US5403734A (en) 1995-04-04
DE3853100D1 (de) 1995-03-30
NO882454D0 (no) 1988-06-03
DK302388D0 (da) 1988-06-03
FI882627A (fi) 1988-12-05
NZ224914A (en) 1991-02-26
FI101306B1 (fi) 1998-05-29
AU625752B2 (en) 1992-07-16
ATE118815T1 (de) 1995-03-15
IE67036B1 (en) 1996-05-15
IE881680L (en) 1988-12-04
FI101306B (fi) 1998-05-29
DE3853100T2 (de) 1995-08-03
DK302388A (da) 1989-02-03
KR890000521A (ko) 1989-03-15
NO179874B (no) 1996-09-23

Similar Documents

Publication Publication Date Title
EP0293934B1 (en) Mutant t-PA with kringle replacement
EP0227462B1 (en) Novel peptide plasminogen activators
EP0293936B1 (en) Tissue plasminogen activator analogs having modified growth factor domains
US5504001A (en) Hybrid plasminogen activator
EP0292009A1 (en) Fibrinolytic proteins
CA1341612C (en) Human tissue plasminogen activator variants and processes
US5200340A (en) Thrombin-activated tissue plasminogen activators
US5385732A (en) Variants of tissue plasminogen activator, compositions and methods of use for same
EP0506821B1 (en) Hybrid protein c
US5149533A (en) Modified t-PA with kringle-/replaced by another kringle
EP0297066B1 (en) Novel fibrinolytic enzymes
IL90146A (en) Glycosylation derivatives of tissue plasminogen activator
US5486471A (en) Tissue plasminogen activator analogs having modified growth factor domains
EP0299706A2 (en) Nonglycosylated plasminogen activator and method of preparation
EP0387380A1 (en) Mutants of urinary plasminogen activator, their production and use
EP0541952A1 (en) Mutant human prourokinase
EP0365597A1 (en) IMPROVED METHODS FOR THE TREATMENT OF VASCULAR DISEASES.
CA1341444C (en) Modified tissue plasminogen activator
US6682733B1 (en) Fibrinolytic enzymes
US5045315A (en) Process for treating thrombosis by administering poly-kringle plasminogen activator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EISAI CO., LTD.

Owner name: ZYMOGENETICS INC.

Owner name: NOVO-NORDISK A/S

17P Request for examination filed

Effective date: 19900112

17Q First examination report despatched

Effective date: 19920228

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 118815

Country of ref document: AT

Date of ref document: 19950315

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3853100

Country of ref document: DE

Date of ref document: 19950330

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2069536

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3016087

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20060519

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060620

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20060624

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20060626

Year of fee payment: 19

Ref country code: GB

Payment date: 20060626

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20060628

Year of fee payment: 19

Ref country code: CH

Payment date: 20060628

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20060630

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060714

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060731

Year of fee payment: 19

BERE Be: lapsed

Owner name: *ZYMOGENETICS INC.

Effective date: 20070630

Owner name: *EISAI CO. LTD

Effective date: 20070630

Owner name: *NOVO NORDISK A/S

Effective date: 20070630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20070628

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070603

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20080101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070630

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20080229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080101

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080101

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070604

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20060628

Year of fee payment: 19

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080104

REG Reference to a national code

Ref country code: FR

Ref legal event code: TQ

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070603